Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, with ICBs administered at flat doses regardless of …
Meta CEO Mark Zuckerberg said the company plans to up its capital expenditures in 2025 as it aims to keep pace with rivals in the…
Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may…
Nature – Analysis of policies for promotion criteria to full professor from academic institutions and government agencies worldwide reveals considerable variation in assessment practices,…
The Legorreta Cancer Center is hosting two visiting oncologists from Kyiv whose work and lives were interrupted when Russia invaded their country in 2022.
PURPOSEWe conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphoma…
Click on the article title to read more.
PURPOSECancer-related financial toxicity occurs frequently and is a key driver of inequities in access to care and disparities in treatment outcomes. Current practices to screen…
Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American regulators.
Nature Cancer – Sanlorenzo et al. propose a strategy to boost immunotherapy by combining topically applied TLR7/8 agonists with systemic interferon-I, sensitizing dendritic cells to…
